Sign in

    James R. Hollingshead

    President and Chief Executive Officer at Insulet Corp
    Board
    Since June 1, 2022
    Age
    61 years
    Education
    Earned a Bachelor of Arts in History and International Relations with Highest Distinction from Stanford University and a Master’s Degree and Ph.D. in Political Science from the University of California, Berkeley.
    Tenure
    Joined the board in July 2019 and was appointed President and Chief Executive Officer on June 1, 2022.

    Also at Insulet Corp

    AMC
    Ana Maria Chadwick
    EVP, Chief Financial Officer and Treasurer
    DM
    Dan Manea
    SVP, Chief Human Resources Officer
    EB
    Eric Benjamin
    EVP, Chief Product and Customer Experience Officer

    About

    James R. Hollingshead has built a distinguished career as a leader in both consulting and digital transformation. His early work in strategy consulting at Deloitte Consulting and as Managing Partner at Monitor Group provided him with deep insights into biotech, high-tech, and telecommunications industries.

    He later led major digital transformation initiatives at ResMed, where he was pivotal in shifting a traditional medical hardware technology model to a SaaS-based digital solutions framework. This experience underscores his ability to drive innovation in complex, regulated environments.

    At Insulet, his leadership as President and Chief Executive Officer reinforces his commitment to strategic growth and digital innovation. His ongoing contributions continuously shape the company's direction in the healthcare and medical device sectors.

    $PODD Performance Under James R. Hollingshead

    Past Roles

    OrganizationRoleDate RangeDetails
    Insulet Corporation (PODD) Director on the Board July 2019 - June 1, 2022 Served as director before promotion to President and CEO
    ResMed, Inc. President, Sleep and Respiratory Care (SRC) business July 2020 - May 2022 Led the transformation to digital SaaS-based solutions
    Deloitte Consulting Senior Partner in the Strategy and Life Sciences practices N/AWorked across multiple industries including biotech, high-tech, and telecommunications
    Monitor Group Managing Partner N/AFocused on strategy consulting initiatives
    Various Companies Other Strategy Consulting Roles N/AAccumulated nearly two decades of experience in strategy consulting across industries

    Fixed Compensation

    Data from  FY 2023
    Component NameAmountPayment ScheduleAdditional Details
    Base Salary$850,000 AnnualFixed annual base salary
    All Other Compensation$9,900 AnnualFixed component for additional payments

    Performance Compensation

    Data from  FY 2023

    Annual Incentive Compensation (AIP)

    MetricWeightThresholdTargetStretch GoalMaximumDetails/Notes
    Adjusted Revenue60%90% of target (50% payout) 100% (100% payout) 104.5% (130% payout) 110% (200% payout) Part of financial metrics (80% of AIP)
    Adjusted EBIT20%85% of target (50% payout) 100% (100% payout) 104.5% (130% payout) 115% (200% payout)
    New Customer Starts6.7%N/AN/AN/AN/APart of strategic metrics (20% of AIP)
    Innovation Pipeline6.7%N/AN/AN/AN/A
    People and Culture6.7%N/AN/AN/AN/A
    • Overall Weighted Payout Factor: 198.8% leading to a final payout of $2,027,760.
    • Grant Details: Date: Feb 28, 2023; Target Award: $1,020,000; Maximum Award: $2,040,000; Grant Date Stock Price: $276.36.

    Performance Stock Units (PSUs)

    MetricWeightThresholdTargetStretch GoalMaximumDetails/Notes
    Adjusted Revenue70%90% of target (50% payout) 100% (100% payout) 104.5% (130% payout) 110% (200% payout) Measured over FY23-FY25
    Adjusted EBIT30%85% of target (50% payout) 100% (100% payout) 104.5% (130% payout) 115% (200% payout)
    • Vesting: Occurs after the FY23-FY25 performance cycle ending Dec 31, 2025.
    • Grant Details: Date: Feb 28, 2023; Fair Value: $5,699,925; Grant Date Stock Price: $276.36.

    Stock Options

    • Grant Date: Feb 28, 2023.
    • Grant Date Fair Value: $1,899,897.
    • Exercise Price: $276.36 per share.
    • Vesting: 25% annually, starting on Feb 28, 2024.
    • Expiration: Feb 28, 2033.
    • Note: No specific performance metrics; value depends on the company’s stock price exceeding the exercise price.

    Long-Term Incentive Award Allocation

    ComponentAllocation %Target/QuantityVesting ScheduleDetails/Notes
    PSUs60%20,625 shares (target); 41,250 shares (max) Vest after FY23-FY25 performance cycleBased on cumulative Adjusted Revenue (70%) & Adjusted EBIT (30%)
    RSUs20%6,875 shares One-third annually over 3 years
    Stock Options20%16,475 options 25% annually over 4 years Exercise Price: $276.36 per share ; part of the long-term award allocation